Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Spellman, Stephen  [Clear All Filters]
2023
Dong J, Buradagunta CStaffi, Zhang T, Spellman S, Bolon Y-T, DeZern AE, Gadalla SM, H Deeg J, Nazha A, Cutler C, et al. Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation. J Hematol Oncol. 2023;16(1):21.
Gragert L, Spellman S, Shaw B, Maiers M. Unrelated Stem Cell Donor HLA Match Likelihoods in the US Registry Incorporating HLA-DPB1 Permissive Mismatching. Transplant Cell Ther. 2023.
Zhang T, Auer P, Dong J, Cutler C, DeZern AE, Gadalla SM, H Deeg J, Nazha A, Carlson K-S, Spellman S, et al. Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study. J Hematol Oncol. 2023;16(1):37.
2022
Johnstone BH, Woods JR, W Goebel S, Gu D, Lin C-H, Miller HM, Musall KM, Sherry AM, Bailey BJ, Sims E, et al. Characterization and Function of Cryopreserved Bone Marrow from Deceased Organ Donors: a Potential Viable Alternative Graft Source. Transplant Cell Ther. 2022.
2021
Story CMcIlwaine, Wang T, Bhatt VRaj, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LAnn, Marsh SGe, et al. Genetics of HLA peptide presentation, and impact on outcomes in HLA-matched allo-HCT. Transplant Cell Ther. 2021.
2020
Dehn J, Chitphakdithai P, Shaw BE, McDonald AA, Devine SM, Burns LJ, Spellman S. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease and Search Prognosis. Biol Blood Marrow Transplant. 2020.
2015
Jindra PT, Conway SE, Ricklefs SM, Porcella SF, Anzick SL, Haagenson M, Wang T, Spellman S, Milford E, Kraft P, et al. Analysis of a genetic polymorphism in the costimulatory molecule TNFSF4 with HSCT outcomes. Biol Blood Marrow Transplant. 2015.
2014
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. Blood. 2014.
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, J Rizzo D, Horowitz M, Confer D, et al. HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry. N Engl J Med. 2014;371(4):339-348.